 |
Moderate increase of secondary hematologic malignancies after
myeloablative radiochemotherapy and autologous stem-cell
transplantation in patients with indolent lymphoma: results of a
prospective randomized trial of the German Low Grade Lymphoma
Study Group. J Clin Oncol. 2004 Dec 15;22(24):4926-33. PMID:
15611507 | Related
articles
|
|
Efficacy and Safety of Tositumomab and Iodine-131 Tositumomab
(Bexxar) in B-Cell Lymphoma, Progressive After Rituximab. J Clin
Oncol. 2004 Dec 21; PMID:
15613695
|
|
Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed
or Refractory B-Cell Non-Hodgkin's Lymphoma. J Clin Oncol. 2004
Dec 21; PMID:
15613697
|
|
Phase II Clinical Experience With the Novel Proteasome
Inhibitor Bortezomib [Velcade] in Patients With Indolent
Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma. J Clin Oncol.
2004 Dec 21; PMID:
15613699
|
|
Results of a prospective randomized clinical trial of
doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)
followed by radiation therapy (RT) versus ABVD alone for stages I,
II, and IIIA nonbulky Hodgkin disease. Blood. 2004 Dec
1;104(12):3483-9. Epub 2004 Dec 1. PMID:
15315964 | Related
articles
|
|
FDA Clears First of Kind Genetic Lab Test - FDA.gov
The Food and Drug Administration (FDA) today cleared for
marketing the first laboratory test system that will allow
physicians to consider unique genetic information from patients in
selecting medications and doses of medications for a wide variety
of common conditions such as cardiac disease, psychiatric disease,
and cancer.
|
|
|
|
Cancer T cell therapy expands ~ Brian Becknell and
Michael A. Caligiuri - nature.com
Dec 2004
|
|
Cancer Care Telephone Workshop: January 26, 2005 1:30 - 2:30
pm Eastern Time
Speakers: Edwin Alyea, MD, Asst. Prof. of Medicine,
Dana-Farber Cancer Institute, Boston, MA
Steven Devine, MD, Asst. Prof of Medicine, Washington Univ.,
St.Louis, MO
Subject: Medical Update on Marrow and Blood Cell
Transplantation for Adults
Register online at www.cancercare.org
|
| Adverse Drug Reactions By Michael W. Loes, M.D. - painconnection.org
"researchers found that more than 106,000 people per year
were reported to have died from adverse drug reactions in the
United States alone.1 Approximately 16,500 were due to
complications from non-steroidal anti-inflammatory agents
(NSAIDs)."
|
| New Drug for Mouth Sores after Bone Marrow Transplants ~ Palifermin Approved for Leukemia, Lymphoma Patients
- cancer.org
|
| New Therapeutic Strategies for Non-Hodgkin's Lymphoma: An Expert Interview With Dr. Richard Fisher
- Medscape
(free login req.)
|
|
Early consolidation by myeloablative radiochemotherapy
followed by autologous stem cell transplantation in first
remission significantly prolongs progression-free survival in
mantle cell lymphoma - results of a prospective randomized trial
of the European MCL network. Blood. 2004 Dec 9; PMID:
15591112
|
|
FDA Approves Kepivance for Severe Oral Mucositis in Cancer
Patients Undergoing Bone Marrow Transplant; Pivotal Phase 3 Study
Published in This Week's New England Journal of Medicine - businesswire.com
Dec 2004
|
|
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in
patients with relapsed and refractory hematologic malignancies. J
Clin Oncol. 2004 Dec 1;22(23):4764-70. PMID:
15570084 | Related
abstracts
|
|
Mercury Fillings: They're Not Risky ~ WebMD Medical News
Mercury Vapors Not Easily Absorbed by Body
|
|
High expression of cyclin B1 predicts a favorable outcome of
patients with follicular lymphoma.
Blood. 2004 Dec 2; PMID:
15576476
|
|
GPC Biotech Announces Clearance from Swiss Regulatory
Authority to - prnews
2004
Initiate Human Clinical Trials with 1D09C3 Anticancer Monoclonal
Antibody
|
|
New marrow transplant method developed at Stanford may
eliminate fatal side effects [of GVHD] - eurekalert.org
By increasing the relative amount of these cells [regulatory
t-cells], he found that he could retain the desired effect of
killing cancerous cells following bone marrow transplantation, but
eliminate the attack on host tissues. "It allows you to throw
out the one effect but not the other," he said. (Dec
2004)
|
| AnorMED announces early results hold promise
for new stem cell mobilizer [AMD3100] in allogeneic transplant for
cancer patients - prnews
Dec 2004
|
| Genetic Target Found for Lymphoma Treatment
- press
release ASH 2004
"These exciting results indicate that Bcl-6 is a new specific
therapeutic target for diffuse large B-cell lymphoma and that BPI
is a potent, highly specific, and non-toxic treatment to address
this target."
|
|
Graft purging in autologous bone marrow transplantation: a
promise not quite fulfilled.
Oncology (Huntingt). 2004 Jun;18(7):867-76; discussion 876-8, 881,
884. Review. PMID:
15255171 | Related
articles
|
|
Less risks for patients participating in early phase cancer
drug trials - news-medical.net
Lay comment: This item suggests
that targeted therapies tend to be safer but less efficacious as
single agents. Note these trends are not blood-cancer
specific. Blood cancers being more sensitive to treatments
than "solid" cancers, including biologic and
immune therapies.
|
|
Marqibo Not Eligible For
Accelerated Approval, Committee Says - fdaadvisorycommittee.com
"Inex/Enzon’s
liposomal vincristine injection Marqibo
should not be eligible for accelerated approval since there are
other therapies for relapsed non-Hodgkin’s lymphoma, FDA’s
Oncologic Drugs Advisory Committee agreed Dec. 1."
|
|
|
| Aplidin(R) now in Phase II trials in both solid and
haematological cancers - mysan.de
"The commencement of the Phase II haematology
trials follows a number of pre-clinical studies and Phase I trials
in which Aplidin(R) demonstrated activity in haematological
malignancies as well as a favorable safety profile.
Aplidin(R) does not present limiting bone marrow toxicity, which
differentiates it from most anti-cancer agents."
|
| Stem cells derived from the umbilical cords of newborn
babies are a viable and effective transplant source for thousands
of leukemia patients who have no other treatment option ~ EurekaAlert.org
2004
|
| Effects of pretransplantation treatment with rituximab on
outcomes of autologous stem-cell transplantation for non-Hodgkin's
lymphoma. J Clin Oncol. 2004 Nov 15;22(22):4561-6. PMID:
15542807
|
| Efficacy and mechanism of action of the proteasome inhibitor
PS-341 [Velcade] in T-cell lymphomas and HTLV-I associated adult
T-cell leukemia/lymphoma. Oncogene. 2004 Nov 15; PMID:
15543232
|
| A new model for predicting infectious complications during
fludarabine-based combination chemotherapy among patients with
indolent lymphoid malignancies. Cancer. 2004 Nov 1;101(9):2042-9. PMID:
15372472
|
| Scientists Unlocking Lymphoma's Secrets - The
microenvironment ~ healthscout.com
"Genetic differences -- not in lymphoma cells, but in immune
cells surrounding the tumor -- may determine how aggressive a
particular case of follicular lymphoma turns out to be"
|
| Phase I Trial of Iodine-131 Tositumomab (Bexxar) With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation for Relapsed Non-Hodgkin's Lymphoma
- jco.org
|
| Off-Brand Biologics: More Questions Than Answers - About.com
|
|
Risks of Cancer Treatment Trials Have Dropped Over Last
Decade - cancersourcern.com
|
| Baseline Tumor Burden Predicts Clinical Outcome in Hodgkin
Lymphoma - leukemia-lymphoma.org/
|
| A Vision for the National Cancer Program in the United States
Posted 10/25/2004 Andrew C. von Eschenbach - medscape
(free login req.)
|
| FDA Grants VELCADE(R) (bortezomib) for Injection Fast Track Status for Relapsed and Refractory Mantle Cell Lymphoma
Tuesday November 2, 4:15 pm ET - biz.yahoo.com/prnews/
|
| Interferon alpha 2b as maintenance therapy in low grade
malignant lymphoma improves duration of remission and survival.
Leuk Lymphoma. 1996 Feb;20(5-6):495-9. PMID:
8833409 | Related
articles
|
|
|
| Gemzar®/Cisplatin/Dexamethasone Effective in Relapsed Hodgkin’s Disease
- cancerconsultants.com
According to a recent article published in Annals of Oncology, the chemotherapy combination consisting of Gemzar® (gemcitabine) and cisplatin (Platinol®) used in addition to the steroid dexamethasone is an effective treatment regimen for patients with relapsed Hodgkin’s lymphoma.
|
| Long-term disease-free survival of patients with advanced
follicular lymphoma after allogeneic bone marrow transplantation.
Br J Haematol. 2004 Nov;127(3):311-21. PMID:
15491292 | Related
articles
|
| Review: Stem cell transplantation in follicular lymphoma:
progress at last?
Bone Marrow Transplant. 2004 Oct 18 PMID:
15489883 | Related
articles
|
| CVP chemotherapy plus Rituximab compared with CVP as
first-line treatment for advanced follicular lymphoma. [322
patient study] Blood. 2004 Oct 19 PMID:
15494430 | Related
articles
Overall and complete response rates were
81% and 41%
in the R-CVP arm vs.
57% and 10%
in the CVP arm, respectively (P < 0.0001).
Median Time to progression: 32 months for
R-CVP vs. 15 months for CVP; P < 0.0001).
|
| Transplantation: Autologous vs. Allogeneic vs. Mini
Hosted by: Sandra J. Horning, MD - lymphoma.org.healthology.com
|
| Myeloablative radiochemotherapy followed by autologous stem
cell transplantation in first remission prolongs progression-free
survival [Compared to consolidation with INF] in follicular
lymphoma: results of a prospective, randomized trial of the German
Low-Grade Lymphoma Study Group - bloodjournal.org
Oct 2004 Commentary
|
|
Autologous Stem-Cell Transplantation Can Be Performed Safely
Without the Use of Blood-Product Support - jco.org
Oct 2004
|
|
Prolonged Clinical and Molecular Remission in Patients With
Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With
Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up.
J Clin Oncol. 2004 Oct 13 PMID:
15483015 | Related
articles
|
|
Clinical Outcome of Lymphoma Patients After Idiotype
Vaccination Is Correlated With Humoral Immune Response and
Immunoglobulin G Fc Receptor Genotype.
J Clin Oncol. 2004 Oct 13 PMID:
15483014 |
|
|
The window of opportunity to comment on a proposed CMS policy
to limit off-label use of cancer drugs will close soon.
Please see Advocacy Alert for
background and how to endorse our appeal.
|
|
Flu Vaccine Shortage and Cancer Patients ~ By Rachael Myers Lowe,
cancerpage.com
|
|
Fludarabine plus mitoxantrone with and without rituximab
versus CHOP with and without rituximab as front-line treatment for
patients with follicular lymphoma.
J Clin Oncol. 2004 Jul 1;22(13):2654-61. Epub 2004 May 24. PMID:
15159414 | Related
articles
|
|
Adjuvant radiotherapy in stage IV diffuse large cell lymphoma
improve outcome.
Leuk Lymphoma. 2004 Jul;45(7):1385-9. PMID:
15359637 | Related
articles
|
|
Adenovirus-mediated intra-lesional (injected inside the tumor)
interferon-gamma gene transfer induces tumor regressions in
cutaneous lymphomas. Blood. 2004 Sep 15;104(6):1631-8. Epub 2004
May 25. PMID: 15161670
| Related
articles
|
|
What Is New in Lymphoma? ~ Bruce D. Cheson, MD Oct 2004
Dr. Cheson is Professor of Medicine, Lombardi Comprehensive Cancer
Center, Georgetown University, Washington, DC. - amcancersoc.org
|
| Warning label added to Rituxan - the label was "revised
to indicate that hepatitis B virus reactivation with fulminant
hepatitis, hepatic failure and death has been reported in some
patients with hematologic malignancies who were treated with
Rituxan since its approval." - pharmexec.com
Oct 2004
|
| Thalidomide and Rituximab Effective for Mantle Cell Lymphoma
- cancerconsultants.com
10/04
|
| Phase II study of paclitaxel and estramustine in patients
with recurrent and refractory non-Hodgkin lymphoma. Cancer. 2004
Sep 28 PMID:
15455357
|
| Cancer Vaccines: Training the Immune System to Fight Cancer
- FDA
consumer mag
|
| Efficacy of rituximab plus chemotherapy in follicular
lymphoma depends on Ki-67 expression.
Pathol Int. 2004 Sep;54(9):667-74. PMID:
15363034 | Related
articles
|
| Rituximab induces different but overlapping sets of genes in
human B-lymphoma cell lines.
Cancer Immunol Immunother. 2004 Sep 23 PMID:
15449038
|
| Immunohistochemical detection of ZAP-70 in 341 cases of
non-Hodgkin and Hodgkin lymphoma; May 2004 - nature.com
|
|
Fludarabine, cyclophosphamide and mitoxantrone for untreated
follicular lymphoma: a report from the non-Hodgkin's lymphoma
co-operative study group. Leuk Lymphoma. 2004
Jun;45(6):1141-7.
PMID:
15359993 | Related
articles
|
|
Survival in young patients (less than 40 years) with
follicular lymphoma: a population based study by the Scotland and
Newcastle Lymphoma Group. Leuk Lymphoma. 2004 Jun;45(6):1149-57. PMID:
15359994
|
|
Gemcitabine and oxaliplatinum: an effective regimen in a
patient with progressive refractory mantle cell lymphoma. Leuk
Lymphoma. 2004 Jun;45(6):1289-91. PMID:
15360015 | Related
articles
|
|
Long Term Outcome in Adolescents with Hodgkin's Lymphoma: Poor
Results using Regimens Designed for Adults. Leuk Lymphoma.
2004;45(8):1579-1585. PMID:
15370209
|
|
Ifosfamide, Epirubicin and Etoposide (IEV) Regimen as Salvage
and Mobilization Therapy for Refractory or Early Relapsing
Patients with Aggressive Non-Hodgkin's Lymphoma.
Leuk Lymphoma. 2004;45(8):1605-1609. PMID:
15370212
|
|
Long-Term Survival With Allogeneic Stem Cell Transplant and
Donor Lymphocyte Infusion Following Salvage Therapy with Anti-CD52
Monoclonal Antibody (Campath) in a Patient with alpha/beta
Hepatosplenic T-Cell Non-Hodgkin's Lymphoma. Leuk Lymphoma.
2004;45(8):1673-1675. PMID:
15370223
|
|
MALT Lymphoma of the Foreskin.
Leuk Lymphoma. 2004;45(8):1699-1701. PMID:
15370229 | Related
articles
|
|
Intra-Vascular Large B-Cell Lymphoma Revealed by a Nephrotic
Syndrome: A One Year Remission Induced by a High Frequency CHOP
and Rituximab.
Leuk Lymphoma. 2004;45(8):1703-1705. PMID:
15370230 | Related
articles
|
|
The Leukemic Presentation of Mantle-cell Lymphoma: Disease
Features and Prognostic Factors in 58 Patients. Leuk Lymphoma.
2004;45(10):2007-2015. PMID:
15370245
"This analysis demonstrates that except for
splenomegaly, survival of MCL patients presenting with leukemia is
not significantly influenced by clinical or tumor characteristics.
Splenectomy is a useful treatment option in this group of
patients."
|
|
Phase II Study of PEND Chemotherapy in Patients with
Refractory/Relapsed Hodgkin Lymphoma.
Leuk Lymphoma. 2004;45(10):2079-2084. PMID:
15370253 | Related
articles
|
|
Randomized comparison of power Doppler ultrasound-directed
excisional biopsy with standard excisional biopsy for the
characterization of lymphadenopathies in patients with suspected
lymphoma.
J Clin Oncol. 2004 Sep 15;22(18):3733-40. PMID:
15365070 | Related
articles
|
|
Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-like T-cell lymphoma: a systematic analysis of 156 patients reported in the literature.
Cancer. 2004 Sep 15;101(6):1404-13. PMID: 15368328
|
|
Late-delayed cerebral involvement in systemic non-Hodgkin
lymphoma.
Cancer. 2004 Sep 15 PMID:
15372481
"Clonal variance between the cerebral and systemic lymphoma
in these patients suggested the possibility that some instances of
late-delayed recurrence in the central nervous system represent a
second, new B-cell lymphoma rather than a true recurrence of the
original systemic tumor, a finding that may have significant
clinical and biologic implications."
|
|
The clinical value of tumor burden at diagnosis in Hodgkin
lymphoma.
Cancer. 2004 Sep 15 PMID:
15372482
|
|
Risk of Non-Hodgkin's Lymphoma and Family History of
Lymphatic, Hematologic, and Other Cancers - Vol. 13, 1415-1421,
September 2004 - aacrjournals.org
|
|
Study: Half of patients with aggressive non-Hodgkin's lymphoma
are under-treated - eurekalert.org
"The reasons for under-treatment included both planned and
unplanned reductions in treatment. Planned reductions were
expected from the beginning of treatment. Unplanned reductions
occurred due to treatment complications. For example, a common,
potentially serious side effect of chemotherapy treatment is
neutropenia, a shortage of infection-fighting white blood cells
...
(Note: The study was funded by Amgen.)
|
| Antisense Drug Targeting STAT-3 Demonstrates Significant Anti-Tumor Activity
- freshnews
press release
|
| Preliminary evidence of relationship between
genetic markers and oncology patient quality of life (QOL). - ASCO
Highlights
"Is there a relationship between the state of cancer
patients' genetic structure and their quality of life? Genetic
variants have been associated with patient toxicity or clinical
outcome. There has been little work done exploring the
relationship between genetic variants and patient QOL."
|
| High-dose thiotepa, melphalan and carboplatin (TMCb)
followed by autologous peripheral blood stem cell transplantation
in patients with lymphoma - a retrospective evaluation.
Bone Marrow Transplant. 2004 Sep 6 PMID:
15354206 | Related
articles
|
| High response rate and manageable toxicity with an
intensive, short-term chemotherapy programme for Burkitt's
lymphoma in adults. Br J Haematol. 2004 Sep;126(6):815-20. PMID:
15352985 | Related
articles
|
| PT-100, a small molecule dipeptidyl peptidase inhibitor, has
potent antitumor effects and augments antibody-mediated
cytotoxicity via a novel immune mechanism.
Cancer Res. 2004 Aug 1;64(15):5471-80. PMID:
15289357 | Related
articles
|
| Infliximab for the treatment of severe steroid
refractory acute graft-versus-host disease in three patients after
allogeneic hematopoietic transplantation.
Leuk Lymphoma. 2003 Dec;44(12):2095-7. PMID:
14959853 | Related
articles
|
| Palliation of relapsed aggressive histology NHL with
high-dose celecoxib and 'metronomic' low-dose cyclophosphamide. - ASCO
2004
|
| Phase II Study of Denileukin Diftitox for
Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma.
J Clin Oncol. 2004 Sep 7 PMID:
15353540 | Related
articles
|
| Allogeneic
“Mini” Stem Cell Transplant Effective for Recurrent Mantle
Cell Lymphoma
- cancerconsultants.com
Sep 2004
|
| Rituxan and late onset neutropenia following Auto stem cell
transplants - haematologica.org
|
| ABVD plus subtotal nodal versus involved-field radiotherapy
in early-stage Hodgkin's disease: long-term results. J Clin Oncol.
2004 Jul 15;22(14):2835-41. Epub 2004 Jun 15. PMID:
15199092 | Related
articles
|
| Strong impact of highly active antiretroviral therapy on
survival in patients with human immunodeficiency virus-associated
Hodgkin's disease. Br J Haematol. 2004 May;125(4):455-62. PMID:
15142115 | Related
articles
|
| Two-weekly or 3-weekly CHOP chemotherapy with or without
etoposide for the treatment of YOUNG patients with good-prognosis
(normal LDH) aggressive lymphomas: results of the NHL-B1 trial of
the DSHNHL. Blood. 2004 Aug 1;104(3):626-33. Epub 2004 Feb 24. PMID:
14982884 | Related
articles
|
| Two-weekly or 3-weekly CHOP chemotherapy with
or without etoposide for the treatment of ELDERLY patients
with aggressive lymphomas: results of the NHL-B2 trial of the
DSHNHL.
Blood. 2004 Aug 1;104(3):634-41. Epub 2004 Mar 11. PMID:
15016643 | Related
articles
|
| Tumor necrosis factor-alpha blockade for the
treatment of acute [steroid resistant] GVHD.
Blood. 2004 Aug 1;104(3):649-54. Epub 2004 Apr 06. PMID:
15069017 | Related
articles
|
| Cardiac toxicity of alemtuzumab in patients
with mycosis fungoides/Sezary syndrome.
Blood. 2004 Aug 1;104(3):655-8. Epub 2004 Apr 08. Review. PMID:
15073032 | Related
articles
|
| Gene expression profiling in Follicular
Lymphoma to assess clinical aggressiveness and to guide the choice
of treatment. Blood. 2004 Sep 2 PMID:
15345589 | Related
abstracts
|
| Treatment Group Refutes ASCO's Stance on
Chemotherapy Resistance Testing - Medscape
(free login req.)
|
| Israeli scientists link Hodgkin's lymphoma to
measles virus - israel21c.org
Israel 21C - Cupertino,CA,USA
|
| The epidemiology of non-Hodgkin's lymphoma.
Oncogene. 2004 Aug 23;23(38):6524-34. PMID:
15322522
|
| T cell immunity induced by live, necrotic, and
apoptotic tumor cells.
J Immunol. 2004 Jul 15;173(2):1012-22. PMID: 15240689
|
| The role of fludarabine in the treatment of
follicular and mantle cell lymphoma.
Cancer. 2004 Sep 1;101(5):883-93. PMID:
15329894
|
| T-Cell Lymphoma Patients Achieve Long Lasting
Responses With Genmab's HuMax-CD4(TM) - prnewswire.com
Sep 2004
|
| Analysis of gene expression in lymphoid cells
can determine lymphoma cancer - Eurekalert.org
"The researchers found that by taking a sample of blood and
doing immunohistochemical analysis for the expression of CDK9 and
CYCLIN T1, they were able to accurately pinpoint the type of
lymphoma--Hodgkins or non-Hodgkins--as well as its stage of
advancement." Sep 2004
|
| Vaccine Boost May Be Needed After Chemotherapy
in Children - Reuters
Health Aug 2004
|
| Phase II Clinical Trial of Interleukin-12 in
Patients with Relapsed and Refractory Non-Hodgkin’s Lymphoma and
Hodgkin’s Disease - aacrjournals.org Aug
2004
"The ability of recombinant human IL-12 therapy to
increase the number of circulating CD8+ cells and induce clinical
remissions in patients with relapsed NHL warrants further investigation
of the drug."
|
| Dennis "D-Roc" Miles, rhythm
guitarist for Ice-T's band Body Count, has died. He was 45 of
complications from lymphoma - miami.com
|
|
BioCryst Receives Orphan Drug Designation for
BCX-1777 in Two Additional Cancer Indications (CLL and related
leukemias) - biz.yahoo.com/prnews
|
|
Modified Bone Marrow Cells Engraft More
Efficiently ~ Karla Gale - Medscape
(free login req.)
|
|
Comparative risk assessment of secondary cancer
incidence after treatment of Hodgkin's disease with photon and
proton radiation. Radiat Res. 2000 Oct;154(4):382-8. PMID:
11023601
|
|
Use of adenoviruses encoding CD40L or IL-2
against B cell lymphoma. Int J Cancer. 2004 Oct 10;111(6):910-20. PMID:
15300803
|
|
Allogeneic Hematopoietic Cell Transplantation
after Fludarabine and 2 Gy Total Body Irradiation for Relapsed and
Refractory Mantle Cell Lymphoma. Blood. 2004 Aug
10 [Epub ahead of print] PMID:
15304387
|
|
Outcome Following Alemtuzumab (CAMPATH-1H) -Containing Reduced Intensity Allogeneic Transplant Regimen for Relapsed and Refractory Non-Hodgkin's Lymphoma (NHL).
Blood. 2004 Aug 10 [Epub ahead of print] PMID: 15304395
|
|
Lymphoma deaths 'unnecessary' Date: 07/08/04 - http://seven.com.au
"Australians are dying unnecessarily from the blood cancer lymphoma each year because it is not treated as a serious health issue, according to a lobby group."
|
|
Predicting response to chemotherapy?
American Society of Clinical Oncology Technology Assessment - jco.org
PDF
Chemotherapy Sensitivity and Resistance Assays ~ Deborah Schrag,
Harinder S. Garewal, Harold J. Burstein, David J. Samson, Daniel
D. Von Hoff, and Mark R. Somerfield for the ASCO Working
Group on Chemotherapy Sensitivity and Resistance Assays
|
| EVENT: PLWC Live Chat Series Nutrition and Cancer
Featured Experts: David Alberts, MD, Cynthia Thomson, PhD, RD
Wednesday, August 18, 2004 2:00 — 3:00 PM ET
Ask a question in advance of the chat ~ plwc.org
|
| Survey: Participate in a survey to help understand why
cancer patients choose to enter or not to enter cancer clinical
trials. - http://advocates.calgb.org/
|
| Old versus new: High dose chlorambucil in the treatment of
lymphoid malignancies. Leuk Lymphoma. 2004 Feb;45(2):271-5. PMID:
15101711
|
| MALT/MZL: Ongoing monoclonal B-cell proliferation is not
common in gastric B-cell lymphoma after combined radiochemotherapy.
J Clin Oncol. 2004 Aug 1;22(15):3039-45. PMID:
15284253
|
| Utility of fine-needle aspiration (FNA) as a diagnostic
technique in lymphoma. J Clin Oncol. 2004 Aug 1;22(15):3046-52. PMID:
15284254 "CONCLUSION Overall, FNA for lymphoma diagnosis
is not helpful, not cost effective, and in addition may misguide
treatment."
|
| Engrafted T-cells and Transplants: Reduced-intensity
conditioning prior to allogeneic transplantation of hematopoietic
stem cells (mini): the need for T cells early after
transplantation to induce a graft-versus-lymphoma effect. Bone
Marrow Transplant. 2004 Jul 26 PMID:
15273707
|
| Study finds that BEAM improves survival: High-dose CEB vs
BEAM with autologous stem cell transplant in lymphoma. Bone Marrow
Transplant. 2004 Jul 26 PMID:
15273714 | Related
abstracts
|
| Hope after autoSCT failure? Myeloablative allogeneic
hematopoietic stem cell transplantation (mini) in patients who
relapse after autologous stem cell transplantation for lymphoma: a
report of the international bone marrow transplant registry.
Blood. 2004 Jul 27 PMID:
15280203 | Related
abstracts
"In summary, alloHSCT is feasible in patients with
lymphoma relapsing after autoHSCT and can result in prolonged
survival for some but is usually not curative. Most likely to
benefit are patients who have an HLA-matched sibling donor, are in
remission, and have a good performance status."
|
| Survival: The addition of rituximab to a combination of
fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly
increases the response rate and prolongs survival as compared to
FCM alone in patients with relapsed and refractory follicular and
mantle cell lymphomas - results of a prospective randomized study
of the German low grade lymphoma study group (GLSG). Blood. 2004
Jul 29 - PMID:
15284112 | Related
abstracts
|
| Presence of simian virus 40 DNA sequences in human lymphoid
and hematopoietic malignancies and their relationship to aberrant
promoter methylation of multiple genes.
Cancer Res. 2004 Jun 1;64(11):3757-60. PMID:
15172980 | Also see Methylation
|
| We are
different: Cancer
Study Sheds New Light on DNA ('copy number polymorphisms' or CNPs)
- separationsnow.com "Initially, Roma [(representational oligonucleotide
microarray analysis] was developed to detect genetic differences
between normal cells and cancer cells. Scientists used the
technique to reveal several genetic duplications and deletions of
DNA segments associated with a variety of human cancers. But that
work also yielded a surprise discovery - large- scale differences
in the DNA of 'normal' cells."
|
| Phase I trial of PXD101 (an HDAC inhibitor) begins in
patients with hematologic cancer -
Cancer Therapy - corporate-ir.net/
|
|
Serum CA125: A Tumor Marker for Monitoring Response to
Treatment and Follow-up in Patients with Non-Hodgkin’s Lymphoma
- theoncologist.alphamedpress.org
|
|
Scientists build on case connecting inflammatory
disease and depression - uiuc.edu/
|
|
Peginterferon Alfa-2a plus Ribavirin for Chronic
Hepatitis C Virus (HCV) Infection in HIV-Infected Patients
(Posted here because HCV is fairly common in lymphoma patients,
and Interferon is sometimes used to treat lymphoma.) - nejm.org
|
|
|
|
Adult Burkitt's Leukemia and
Lymphoma.
Blood. 2004 Jul 20 [Epub ahead of print] PMID:
15265787
|
|
Bone marrow histological patterns can
predict survival of patients with grade 1 or 2 follicular
lymphoma:
a study from the Groupe d'Etude des Lymphomes Folliculaires.
Br J Haematol. 2004 Aug;126(3):364-71. PMID:
15257708
|
|
Accentia
Biopharmaceuticals - investigational idiotype vaccine: BiovaxID
Toll-free Information on clinical trials: 1-877-654-6052 |
website: http://www.accentia.net/
|
| Public Registration of Clinical Trials ~ Robert Steinbrook, M.D. -
NEJM 2004
|
| Cancer Immunotherapy Inches Forward - the-scientist.com
|
| Is more better? Two parallel trials suggest that intensified CHOP is superior to standard CHOP in the
management of aggressive NHL. "The authors of
these papers conclude that they have defined new
"preferred therapies" for histologically aggressive NHL,
but the standard therapy today (although not when these
trials were started) is not CHOP-21, it is CHOP-21 plus
rituximab. Although rituximab may add further to the
benefits of CHOP-14 or CHOEP-21 (CHOP plus etoposide),
it is possible that the use of rituximab may negate any
benefits due to dose intensification. In the rituximab
era, it remains unclear whether "more is better," and
further trials are required." - bloodjournal.org
|
|
Modified magrath regimens for adults with Burkitt and Burkitt-like
lymphomas: preserved efficacy with decreased toxicity. Leuk
Lymphoma. 2004 Apr;45(4):761-7. PMID:
15160953
|
|
Rituximab in a patient with acute renal failure due to B-cell
lymphomatous infiltration of the kidneys.
Leuk Lymphoma. 2004 Apr;45(4):819-20. PMID:
15160963
|
|
Prognostic Factors in Patients With Aggressive Non-Hodgkin's
Lymphoma Treated by Front-Line Autotransplantation After Complete
Remission: A Cohort Study by the Groupe d'Etude des Lymphomes de
l'Adulte. J Clin Oncol. 2004 Jul 15;22(14):2826-34. PMID:
15254050
|
|
Immunochemotherapy with rituximab and temozolomide for central
nervous system lymphomas.
Cancer. 2004 Jul 1;101(1):139-45. PMID:
15221999
|
|
Expression of BLyS and Its Receptors in B-Cell Non-Hodgkin
Lymphoma: Correlation With Disease Activity and Patient Outcome.
Blood. 2004 Jul 13 PMID:
15251985
|
|
Lymphoma-Specific Genetic Aberrations in Microvascular Endothelial Cells in B-Cell Lymphomas
Berthold Streubel, M.D., Andreas Chott, M.D., Daniela Huber, Markus Exner, M.D., Ulrich Jäger, M.D., Oswald Wagner, M.D., and Ilse Schwarzinger, M.D.
~ NEJM
|
|
Stem cell transplantation for peripheral T-cell lymphomas.
Leuk Lymphoma. 2004 Mar;45(3):441-6. Review. PMID:
15160904
|
|
Use of iodine 131I-tositumomab radioimmunotherapy in a patient
with Waldenstrom's macroglobulinemia.
Leuk Lymphoma. 2004 Mar;45(3):591-5. PMID:
15160923
|
|
Long-term results of the first Italian Association of
Pediatric Hematology and Oncology protocol for the treatment of
pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92).
Cancer. 2004 Jul 15;101(2):385-94. PMID:
15241838
|
|
Ocular presentation of primary central nervous system
lymphoma: diagnosis and treatment.
Br J Haematol. 2004 Jul;126(2):202-8. PMID:
15238140
|
|
Strong Expression of FOXP1 Identifies a Distinct Subset of
Diffuse Large B-Cell Lymphoma Patients with Poor Outcome. Blood.
2004 Jul 6 PMID:
15238418
|
|
Myeloablative radiochemotherapy followed by autologous stem
cell transplantation in first remission prolongs progression-free
survival in follicular lymphoma - results of a prospective
randomized trial of the German Low-Grade Lymphoma Study Group (GLSG).
Blood. 2004 Jul PMID:
15238420
|
|
FDA fast-tracks Cell Therapeutics' lymphoma treatment (pixantrone)
- bizjournal.com
Jul 2004
Also see Studies
for pixantrone
|
|
Melatonin as a radioprotective agent: a review.
Int J Radiat Oncol Biol Phys. 2004 Jul 1;59(3):639-53. PMID: 15183467
|
|
Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol
Imaging. 2003 Jun;30 Suppl 1:S117-27.
Epub 2003 May 13. Review. PMID:
12748831
|
|
Liposome-Encapsulated Doxorubicin in Combination With Standard
Agents (cyclophosphamide, vincristine, prednisone) in Patients
With Newly Diagnosed AIDS-Related Non-Hodgkin's Lymphoma: Results
of Therapy and Correlates of Response. J Clin Oncol. 2004 Jul
1;22(13):2662-70. PMID:
15226333
|
|
Corixa Files Supplemental Application for Expanded Use of
BEXXAR - Businesswire
|
|
Fenretinide
(synthetic analog of retinoic acid) enhances rituximab-induced
cytotoxicity against B-cell lymphoma xenografts through a
caspase-dependent mechanism. Blood. 2004 May 1;103(9):3516-20. PMID: 14695237
| Related
articles
|
|
The Virus and the Vaccine ~ Investigational journalists have written a book on the SV40
and it's possible role in the increased incidence of lymphoma and
other cancers. - thevirusandthevaccine.com
|
|
Treatment of Non-Hodgkin's Lymphoma: Next Steps - medscape.com
2004 (free login req.)
Review of progress for Follicular, SLL, Diffuse Large Cell, and
Mantle Cell.
|
| Infection-Driven Lymphomas: The List Grows - hematology.org
2004
|
| PAL exhibit at ASCO 2004. A diary describing our experience
and our message. With pictures - PAL
|
| Infused CD34 cell dose, but not tumour cell content of
peripheral blood progenitor cell grafts, predicts clinical outcome
in patients with diffuse large B-cell lymphoma and follicular
lymphoma grade 3 treated with high-dose therapy. Br J Haematol.
2004 Jun;125(5):605-12. PMID:
15147376 Also see Lazarus.pdf
|
| Improved outcome when B-cell lymphoma is treated with
combinations of immunoliposomal anticancer drugs targeted to both
the CD19 and CD20 epitopes (antigens). Clin Cancer Res. 2004 Apr
1;10(7):2530-7.
PMID:
15073133 | Related
Articles | Background
|
| Costly Cancer Drugs Pose Hard Questions
Daily Policy Digest ~ Health Issues / Drugs and Technologies ~ Friday, June 20, 2003 -
ncpa.org
|
| Association between SV40 and non-Hodgkin's lymphoma.
Leuk Lymphoma. 2003;44 Suppl 3:S33-9. PMID:
15202523 | Related
articles
|
| Graft-vs.-lymphoma |
